Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

New nine-valent HPV vaccine has potential to dramatically reduce cervical cancer rates

A multinational study on a diverse group of women shows that a new nine-valent human papillomavirus (HPV) vaccine prevents infections and disease associated with the vaccine types, according to a paper published today in The New England Journal of Medicine.

19 Feb 2015

HPV vaccination does not affect sexual behaviours

Research has shown that human papillomavirus (HPV) vaccination is not associated with increases in sexually transmitted infections (STIs).

10 Feb 2015

HPV vaccine does not increase rates of STIs in adolescent females

Receiving the human papillomavirus vaccine does not increase rates of sexually transmitted infections (STIs) in adolescent females. The vaccine, which can prevent cervical cancer in women, has had a low uptake, partly because of concerns about how it will affect adolescent sexual activity.

10 Feb 2015

New model proposed for predicting outcomes more accurately in HPV-related throat cancer patients

Researchers at the Princess Margaret Cancer Centre are proposing a new model to enable doctors to predict outcomes more accurately for patients with throat cancers specifically caused by Human Papillomavirus (HPV).

10 Feb 2015

TOSH Program aims to improve oral-systemic health

Improving oral health is a leading population health goal; however, curricula preparing health professionals have a dearth of oral health content and clinical experiences. Funded by a grant from the Health Resources and Service Administration, New York University College of Nursing's Teaching Oral-Systemic Health Program is working to build interprofessional oral health workforce capacity which addresses a significant public health issue, increases oral health care access, and improves oral-systemic health across the lifespan.

23 Jan 2015

UTMB study reveals that only about half of teenage girls get HPV vaccine at the recommended age

It's a virus that is responsible for almost all cases of cervical cancer but a new study by University of Texas Medical Branch at Galveston researchers indicates that only about half of the girls receive the vaccine at the recommended age to best protect themselves.

22 Jan 2015

Two medical organizations recommend use of HPV test for cervical cancer screening

Two leading medical organizations say that using a Human papillomavirus (HPV) test alone for cervical cancer screening is an effective alternative to the current recommendation for screening with either cytology (the Pap test) alone or co-testing with cytology and HPV testing.

12 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

Quadrivalent HPV vaccine cleared of multiple sclerosis risk

A study of almost 4 million girls and women allays fears that receipt of the quadrivalent human papillomavirus vaccine could increase the risk of developing multiple sclerosis, or other demyelinating disorders.

7 Jan 2015

Study sheds light on common psychosocial barriers affecting HPV vaccination in Puerto Rico

Young Puerto Rican women and their mothers know little about the human papillomavirus (HPV) and cervical cancer, according to researchers at The University of Texas Health Science Center at Houston School of Public Health.

6 Dec 2014

Empathic partnership: A health care model for marginalized populations

Sitting on an exam table in a flimsy gown can intimidate anyone. If you also happen to be lesbian, gay or bisexual, the experience can be even worse.

5 Dec 2014

MRIGlobal awarded $3 million contract to provide HPV vaccine

MRIGlobal today announced that it has been awarded a $3 million contract amendment from the National Cancer Institute's PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV, the most common sexually transmitted infection in the United States. MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial.

4 Dec 2014

New WHO guidance provides cervical cancer control and prevention approach

New guidance from WHO aims to help countries better prevent and control cervical cancer. The disease is one of the world's deadliest - but most easily preventable - forms of cancer for women, responsible for more than 270 000 deaths annually, 85% of which occur in developing countries.

3 Dec 2014

UNM Cancer Center program to help new scientists learn nuances of conducting science

create a set of systems to track people, projects and money. But scientists' formal training doesn't always include business classes. To bridge this gap, Michelle Ozbun, PhD, at the University of New Mexico Cancer Center, is improving a program that helps new scientists learn nuances of conducting science.

3 Dec 2014

Genticel completes patient enrollment for ProCervix phase II study

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix.

14 Nov 2014

McGill study helps identify people at risk for oral human papillomavirus

Oral human papillomavirus (HPV) infections were more common among men who had female partners with oral and/or genital HPV infection, suggesting that the transmission of HPV occurs via oral-oral and oral-genital routes, according to a McGill University study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

13 Nov 2014

Eight million US women skip cervical cancer screening in the past five years

Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened.

6 Nov 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

Japanese mushroom extract shows promise in eradicating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.

29 Oct 2014

Population Council to present research on novel approaches to HIV prevention at HIV R4P 2014

The Population Council will present new research on novel approaches to HIV, sexually transmitted infections (STIs), and unintended pregnancy prevention at the HIV Research for Prevention Conference, (HIV R4P) in Cape Town, South Africa. HIV R4P, which runs 28–31 October, is the first global scientific meeting dedicated exclusively to research on biomedical HIV prevention.

27 Oct 2014